GLP-1 Therapy Start Guide

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Starting GLP-1 therapy begins with a comprehensive medical evaluation—not just a prescription. You'll need baseline metabolic labs, cardiovascular assessment, and a clear discussion with your provider about your specific health profile, weight history, and metabolic risk factors.

Many patients focus on dosing schedules but overlook the foundational step: understanding whether GLP-1 therapy aligns with your metabolic phenotype. PlexusDx approaches this with precision wellness principles, examining biomarker patterns and genetic predispositions to help guide more informed treatment decisions with your healthcare team.

Medical Readiness: Key Evaluations Before Starting

Before initiating GLP-1 therapy, your healthcare provider should order baseline labs including fasting glucose, HbA1c, lipid panel, and thyroid function. These measurements establish your metabolic baseline and help identify any contraindications or comorbidities that influence dosing strategy and monitoring frequency.

Cardiovascular assessment is equally important. GLP-1 medications reduce cardiovascular events in patients with established disease, but your provider needs current blood pressure, heart rate, and potentially an EKG depending on age and risk factors. This evaluation shapes your initiation timeline and dose escalation plan.

Dosing Protocols: From Microdose to Standard Initiation

GLP-1 dosing strategies vary by individual metabolic sensitivity, gastric tolerance, and treatment goals. Some patients respond well to standard weekly protocols, while others benefit from lower-dose, more frequent initiation to minimize nausea and optimize adherence during the first 4-8 weeks.

Protocol Type	Starting Dose	Escalation Pattern	Typical Timeline
Microdose GLP-1	0.1–0.25 mg weekly	Gradual increase every 1-2 weeks	8–12 weeks to therapeutic range
Standard Initiation (Injectable)	0.25 mg weekly	Increase 0.25 mg weekly up to 1.0 mg	4–6 weeks to maintenance
Oral Protocol	3–7 mg daily	Titrate by 3–7 mg based on response	2–4 weeks assessment
Dual Compound (GLP-Squared)	Individualized	Provider-directed based on biomarkers	Customized per clinical profile

Understanding Your Metabolic Phenotype Before Dosing

Not all patients metabolize GLP-1 medications at the same rate or with identical tolerability. Your baseline insulin sensitivity, gastric emptying patterns, and inflammatory markers influence optimal dosing speed and target dose. A provider familiar with these nuances can tailor initiation to your metabolic profile.

PlexusDx's Precision Peptide Genetic Test examines predispositions in key peptide pathways—including GLP1R, GIPR, FTO, and MC4R variants—which may help provide context for how your body responds to GLP-1 therapy. This information, interpreted with your provider, can support a more personalized initiation strategy.

Safety Considerations and Who Should Delay or Avoid Initiation

Certain populations require medical caution before starting GLP-1 therapy: those with personal or family history of medullary thyroid carcinoma, active pancreatitis, severe kidney disease, or uncontrolled diabetic retinopathy. Pregnancy is a contraindication; planning pregnancy requires stopping GLP-1 at least 2 months prior.

Patients taking other weight-loss medications, certain diabetes drugs, or blood pressure medications should coordinate with their provider before initiation to prevent drug interactions. Your healthcare team will assess these factors and determine if a delayed start or adjusted protocol is appropriate for your clinical situation.

How PlexusDx Supports a More Personalized Approach

PlexusDx's approach to GLP-1 initiation emphasizes precision—understanding your individual biomarker profile and genetic predispositions before choosing a dosing protocol. The Precision Peptide Genetic Test reveals variants in GLP1R, GIPR, FTO, and MC4R pathways, which may help provide context for how your metabolic system responds to GLP-1 stimulation. This information should be interpreted with your qualified healthcare provider.

The Precision Peptide Genetic Test does not predict exact medication response or guarantee outcomes. Instead, it identifies genetic predispositions in peptide signaling pathways. For example, certain GLP1R variants are associated with variable receptor sensitivity, but this represents population-level association data, not individual certainty. Combined with your clinical labs and symptom history, these insights can support a more informed conversation about protocol selection.

Using biomarker and genetic context alongside standard medical evaluation creates a more complete picture before starting therapy. This precision approach may help your provider select between microdose protocols, standard initiation, oral formulations, or dual-compound strategies—increasing the likelihood of tolerability and sustained adherence during the critical first months of treatment.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Do I need labs before starting GLP-1 therapy?

Yes. Your provider should order fasting glucose, HbA1c, lipid panel, liver and kidney function, and thyroid markers. These establish baseline metabolic health and screen for contraindications before initiating therapy.

What's the difference between microdose and standard GLP-1 initiation?

Microdose protocols use lower weekly doses (0.1–0.25 mg) with slower escalation, often better tolerated by sensitive patients. Standard initiation begins at 0.25 mg and increases weekly. Your provider chooses based on your metabolic profile and gastric tolerance history.

How much does compounded GLP-1 therapy cost at PlexusDx?

PlexusDx offers compounded semaglutide injection $149/mo, oral semaglutide from $249/mo, and microdose GLP-1 protocol at $129/month, all from licensed 503A pharmacies. Pricing varies by formulation and dosage strength.

What side effects should I expect when starting GLP-1?

Nausea, constipation, and reduced appetite are common during early weeks. Slower dose escalation reduces side effect severity. Dehydration and pancreatitis are rare but serious—report severe abdominal pain or persistent vomiting to your provider immediately.

How can the Precision Peptide Genetic Test help with my GLP-1 start?

The test reveals predispositions in GLP1R, GIPR, FTO, and MC4R pathways, which may provide context for your metabolic response to GLP-1. Interpreted with your clinical labs and medical history, this information can support your provider's protocol selection for safer, more personalized initiation.

How Do I Start Taking Ozempic: A Step-by-Step Guide